Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

beta-Endorphin and schizophrenia

P A Berger, S J Watson, H Akil

    Archives of General Psychiatry
    |June 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Adolescent Binge Drinking Is Associated With Accelerated Decline of Gray Matter Volume.

    Cerebral cortex (New York, N.Y. : 1991)·2021
    Same author

    The neural correlates of priming emotion and reward systems for conflict processing in alcoholics.

    Brain imaging and behavior·2016
    Same author

    Brain responses to emotional salience and reward in alcohol use disorder.

    Brain imaging and behavior·2015
    Same author

    Dissociation of preparatory attention and response monitoring maturation during adolescence.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2013
    Same author

    Midbrain-driven emotion and reward processing in alcoholism.

    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2013
    Same author

    White matter fiber compromise contributes differentially to attention and emotion processing impairment in alcoholism, HIV-infection, and their comorbidity.

    Neuropsychologia·2012
    Same journal

    Reviewers Who Completed a Review During 2011.

    Archives of general psychiatry·2017
    Same journal

    Conflicts of interest-reply.

    Archives of general psychiatry·2013
    Same journal

    Epidemiologic evidence concerning the bereavement exclusion in major depression-reply.

    Archives of general psychiatry·2013
    Same journal

    This month in archives of general psychiatry.

    Archives of general psychiatry·2013
    Same journal

    About this journal.

    Archives of general psychiatry·2013
    Same journal

    This month in archives of general psychiatry.

    Archives of general psychiatry·2013
    See all related articles

    Beta-endorphin administration in chronic schizophrenia patients showed a significant increase in prolactin levels and minor EEG changes. While not clinically obvious, eight patients experienced slight symptom improvement, suggesting potential therapeutic avenues.

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Endocrinology

    Background:

    • Chronic schizophrenia is a complex mental disorder with limited treatment options.
    • Beta-endorphin, an endogenous opioid peptide, plays a role in mood and stress regulation.
    • Investigating novel therapeutic agents for schizophrenia is crucial.

    Purpose of the Study:

    • To evaluate the effects of intravenous beta-endorphin in patients with chronic schizophrenia.
    • To assess the impact of beta-endorphin on serum prolactin levels and electroencephalogram (EEG) activity.
    • To determine any clinical changes in schizophrenic symptoms following beta-endorphin administration.

    Main Methods:

    • A double-blind, crossover study involving nine male patients with chronic schizophrenia.

    Related Experiment Videos

  • Comparison of a single 20-mg intravenous injection of beta-endorphin versus saline.
  • Measurement of plasma beta-endorphin concentrations, serum prolactin levels, and EEG parameters.
  • Assessment of schizophrenic symptom severity.

    • Main Results:

    • Bolus injection yielded higher plasma beta-endorphin concentrations compared to slow infusion.
    • Intravenous beta-endorphin significantly increased serum prolactin levels in patients.
    • One patient showed similar EEG alpha power increases with both morphine sulfate and beta-endorphin.
    • Eight patients exhibited statistically significant, though not clinically apparent, improvements in schizophrenic symptoms.

    Conclusions:

    • Intravenous beta-endorphin administration is feasible and affects physiological markers in schizophrenia.
    • Beta-endorphin's impact on prolactin and EEG warrants further investigation in psychiatric contexts.
    • The subtle clinical improvements suggest a need for further research into beta-endorphin's therapeutic potential for schizophrenia.